Resubmission After Withdrawal: US FDA’s Mavenclad Approval Acknowledges Long Regulatory History
Executive Summary
EMD Serono’s multiple sclerosis drug joins small cadre of products that survived a refuse to file letter and NDA withdrawal; chart details recent RTFs and application withdrawals.
You may also be interested in...
US FDA Filing Mistake For Fintepla Dents Zogenix
Zogenix seems only to have itself to blame for an unexpected refusal to file letter from the US agency for its novel treatment for Dravet syndrome that sent its shares tumbling by 31% on NASDAQ in after-hours trading.
Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.